Perifosine Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

Numerous Phase 1, Phase 2, and Phase 3 clinical trials have evaluated perifosine as monotherapy and combination therapy for conditions including solid tumors, colon cancer, pediatric malignancies, soft tissue sarcomas, malignant gliomas, and Waldenström's macroglobulinemia. Sponsored by academic centers, cooperative networks, and industry entities such as the National Cancer Institute, Memorial Sloan Kettering Cancer Center, and AEterna Zentaris, these mostly completed or terminated studies represent extensive efforts to assess perifosine as a targeted therapy for refractory or advanced neoplasms.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00590954	COMPLETED	Malignant Gliomas; CNS; Brain Cancer; Cancer	Memorial Sloan Kettering Cancer Center	2006-05	PHASE2
NCT01051557	COMPLETED	Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm	National Cancer Institute (NCI)	2010-01-27	PHASE1; PHASE2
NCT02238496	COMPLETED	Brain Tumor, Recurrent; Glioblastoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Glioma	Andrew B Lassman, MD	2014-12-08	PHASE1
NCT00776867	COMPLETED	Solid Tumors	Memorial Sloan Kettering Cancer Center	2008-10	PHASE1
NCT01049841	COMPLETED	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center	2010-01	PHASE1
NCT01224730	COMPLETED	Cancer	AEterna Zentaris	2012-01-24	PHASE1
NCT01002248	TERMINATED	Multiple Myeloma	AEterna Zentaris	2009-12	PHASE3
NCT00847366	COMPLETED	Non Small Cell Lung Cancer; Solid Tumors; Metastatic Breast Cancer; Sarcomas	AEterna Zentaris	2008-05
NCT00415064	COMPLETED	Multiple Myeloma	AEterna Zentaris	2006-12	PHASE1
NCT00431054	COMPLETED	Ovarian Cancer	M.D. Anderson Cancer Center	2007-02	PHASE1
NCT00301938	COMPLETED	Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Blastic Phase Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasms; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia	National Cancer Institute (NCI)	2005-12	PHASE1
NCT01097018	COMPLETED	Colorectal Cancer	AEterna Zentaris	2010-04	PHASE3
NCT01224730	Completed	Cancer	AEterna Zentaris	2012-01-24	Phase 1
NCT00873457	COMPLETED	Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	Daphne Friedman	2009-08	PHASE2
NCT00398814	COMPLETED	Renal Cancer; Tumors	AEterna Zentaris	2006-10	PHASE1
NCT00398710	COMPLETED	Waldenström's Macroglobulinemia	AEterna Zentaris	2006-10	PHASE2
NCT00389077	COMPLETED	Tumors; Lymphomas	AEterna Zentaris	2005-01	PHASE2
NCT00498966	COMPLETED	Kidney Cancer	AEterna Zentaris	2007-07	PHASE2
NCT01048580	COMPLETED	Colon Cancer	AEterna Zentaris	2009-10	PHASE1
NCT00401388	COMPLETED	Chondrosarcomas; Alveolar Soft Part Sarcomas; Extra Skeletal Myxoid Chondrosarcomas	AEterna Zentaris	2006-11	PHASE2
NCT00398879	COMPLETED	Colon Cancer	AEterna Zentaris	2005-08	PHASE2
NCT00399789	COMPLETED	Non Small Cell Lung Cancer	AEterna Zentaris	2004-09	PHASE1; PHASE2
NCT00375791	COMPLETED	Multiple Myeloma	AEterna Zentaris	2005-12	PHASE2
NCT00401011	COMPLETED	Multiple Myeloma; Multiple Myeloma in Relapse	AEterna Zentaris	2006-08	PHASE1; PHASE2
NCT00455559	COMPLETED	Gastrointestinal Stromal Tumors	AEterna Zentaris	2006-08	PHASE2
NCT00391560	COMPLETED	Leukemia	AEterna Zentaris	2006-10	PHASE2
NCT00448721	COMPLETED	Renal Cell Carcinoma	AEterna Zentaris	2007-03	PHASE2
NCT00399087	COMPLETED	Neoplasms	AEterna Zentaris	2004-11	PHASE1
NCT01049841	Completed	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	2010-01	Phase 1
NCT01048580	Completed	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	2009-10	Phase 1
NCT00422656	COMPLETED	Waldenstrom's Macroglobulinemia	Dana-Farber Cancer Institute	2006-09	PHASE2
NCT00399126	COMPLETED	Neoplasms	AEterna Zentaris	2004-11	PHASE1
NCT00058214	TERMINATED	Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer	National Cancer Institute (NCI)	2003-03	PHASE2
NCT00399152	COMPLETED	Renal Cancer; GIST	AEterna Zentaris	2006-10	PHASE1
NCT00776867	Completed	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	2008-10	Phase 1
NCT00054145	COMPLETED	Breast Cancer	University Health Network, Toronto	2003-06	PHASE2
NCT00062387	TERMINATED	Head and Neck Cancer	National Cancer Institute (NCI)	2003-05	PHASE2
NCT00053924	COMPLETED	Pancreatic Cancer	University Health Network, Toronto	2003-05	PHASE2
NCT00064324	COMPLETED	Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma	National Cancer Institute (NCI)	2003-06	PHASE2
NCT00053794	COMPLETED	Endometrial Cancer; Sarcoma	NCIC Clinical Trials Group	2003-06-09	PHASE2
NCT00053781	COMPLETED	Melanoma (Skin)	NCIC Clinical Trials Group	2003-06-20	PHASE2
NCT00398697	COMPLETED	Neoplasms	AEterna Zentaris	2004-08	PHASE1
NCT00060437	COMPLETED	Prostate Cancer	National Cancer Institute (NCI)	2003-10	PHASE2
NCT00019656	COMPLETED	Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	1999-08	PHASE1
NCT00005794	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	University of Wisconsin, Madison	2000-02	PHASE1
NCT00059982	COMPLETED	Pancreatic Cancer	Eastern Cooperative Oncology Group	2003-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2020-10-19)

Check the Perifosine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Perifosine targets the pleckstrin homology domain of Akt to block its membrane translocation and activation, which subsequently modulates membrane lipid composition and shifts the balance toward pro-apoptotic SAPK/JNK signaling over anti-apoptotic MAPK pathways. This biochemical disruption induces cell cycle arrest and apoptosis, thereby suppressing cellular proliferation in malignancies such as colon cancer, malignant gliomas, and advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).